-
Key Brands
-
Revenue
-
Performance
| Arixtra | Diprivan | Fraxiparine | Sustanon | Ultiva | Xylocaine |
|---|---|---|---|---|---|
|
Anticoagulant |
General |
Low molecular |
Testosterone |
Opioid analgesic |
Regional |
Revenue by segment (%)
21%
of Group revenue
28%
of Group gross profit
- Asia33
- Americas25
- Europe CIS 20
- Africa Middle East13
- Australasia9
Revenue
| Revenue |
2024 R’million |
2023 R’million |
%Change Reported |
CER |
|---|---|---|---|---|
|
Asia |
3 112 |
4 701 |
(34) |
(35) |
|
Americas |
2 395 |
1 955 |
23 |
12 |
|
Europe CIS |
1 903 |
2 116 |
(10) |
(15) |
|
Africa Middle East |
1 218 |
777 |
57 |
58 |
|
Australasia |
856 |
836 |
2 |
- |
|
Total |
9 484 |
10 385 |
(9) |
(12) |
|
Gross profit (%) |
58,2 |
60,6 |
|
|
Injectables revenue decreased by 9% to R9 484 million, primarily due to the effects of China’s VBP.
Revenue in Asia fell by 34%, while Europe CIS saw a 10% decline, mainly driven by the downturn in
Russia. In China, the inclusion of Fraxiparine and Diprivan in the national VBP list led to declines in both
volume and price, particularly in the latter half of the financial year. The decline was partly offset by
product acquisitions in South Africa and strong growth in Brazil. The strategic acquisition of the Sandoz
business in China is expected to sustainably de-risk the injectables segment from FY2025 onwards.
The gross profit margin of 58,2% (FY2023: 60,6%) was influenced by VBP partly offset by cost savings from the continuing insourcing of sterile production.
The gross profit margin of 58,2% (FY2023: 60,6%) was influenced by VBP partly offset by cost savings from the continuing insourcing of sterile production.
